{
    "Trade/Device Name(s)": [
        "B\u00dcHLMANN fCAL turbo",
        "CALEX Cap"
    ],
    "Submitter Information": "B\u00dcHLMANN Laboratories AG",
    "510(k) Number": "K232057",
    "Predicate Device Reference 510(k) Number(s)": [
        "K191718"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NXO"
    ],
    "Summary Letter Date": "February 6, 2024",
    "Summary Letter Received Date": "January 29, 2024",
    "Submission Date": "February 5, 2024",
    "Regulation Number(s)": [
        "21 CFR 866.5180"
    ],
    "Regulation Name(s)": [
        "Fecal calprotectin immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Calprotectin"
    ],
    "Specimen Type(s)": [
        "Human stool"
    ],
    "Specimen Container(s)": [
        "CALEX Cap",
        "Manual weighing extraction tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Clinical chemistry analyzers",
        "Roche cobas c501",
        "Roche cobas c502"
    ],
    "Method(s)/Technology(ies)": [
        "Particle-enhanced turbidimetric immunoassay (PETIA)"
    ],
    "Methodologies": [
        "Immunoparticle agglutination",
        "Turbidity measurement",
        "Quantitative immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Tube",
        "Reagent Kit",
        "Calibrator Kit",
        "Control Kit"
    ],
    "Document Summary": "FDA 510(k) summary for B\u00dcHLMANN fCAL turbo PETIA for quantifying fecal calprotectin in human stool using CALEX Cap extraction.",
    "Indications for Use Summary": "Quantitative measurement of fecal calprotectin in human stool to aid diagnosis of inflammatory bowel disease (IBD), specifically Crohn's disease and ulcerative colitis, and to differentiate IBD from irritable bowel syndrome (IBS) in conjunction with laboratory and clinical findings.",
    "fda_folder": "Immunology"
}